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Abstract
The alkylphospholipid analog miltefosine (hexadecylphosphocholine) is a membrane-directed antitumoral and antil-
eishmanial drug belonging to the alkylphosphocholines, a group of synthetic antiproliferative agents that are pro-
mising candidates in anticancer therapy. A variety of mechanisms have been suggested to explain the actions of
these compounds, which can induce apoptosis and/or cell growth arrest. In this review, we focus on recent
advances in our understanding of the actions of miltefosine and other alkylphospholipids on the human hepatoma
HepG2 cell line, with a special emphasis on lipid metabolism. Results obtained in our laboratory indicate that milte-
fosine displays cytostatic activity and causes apoptosis in HepG2 cells. Likewise, treatment with miltefosine pro-
duces an interference with the biosynthesis of phosphatidylcholine via both CDP-choline and
phosphatidylethanolamine methylation. With regard to sphingolipid metabolism, miltefosine hinders the formation
of sphingomyelin, which promotes intracellular accumulation of ceramide. We have demonstrated for the first time
that treatment with miltefosine strongly impedes the esterification of cholesterol and that this effect is accompa-
nied by a considerable increase in the synthesis of cholesterol, which leads to higher levels of cholesterol in the
cells. Indeed, miltefosine early impairs cholesterol transport from the plasma membrane to the endoplasmic reticu-
lum, causing a deregulation of cholesterol homeostasis. Similar to miltefosine, other clinically-relevant synthetic
alkylphospholipids such as edelfosine, erucylphosphocholine and perifosine show growth inhibitory effects on
HepG2 cells. All the tested alkylphospholipids also inhibit the arrival of plasma-membrane cholesterol to the endo-
plasmic reticulum, which induces a significant cholesterogenic response in these cells, involving an increased gene
expression and higher levels of several proteins related to the pathway of biosynthesis as well as the receptor-
mediated uptake of cholesterol. Thus, membrane-targeted alkylphospholipids exhibit a common mechanism of
action through disruption of cholesterol homeostasis. The accumulation of cholesterol within the cell and the
reduction in phosphatidylcholine and sphingomyelin biosyntheses certainly alter the ratio of choline-bearing phos-
pholipids to cholesterol, which is critical for the integrity and functionality of specific membrane microdomains
such as lipid rafts. Alkylphospholipid-induced alterations in lipid homeostasis with probable disturbance of the
native membrane structure could well affect signaling processes vital to cell survival and growth.
Review
Introduction - Alkylphospholipid analogs as
membrane-directed drugs
Alkylphospholipid (APL) derivatives are novel cytostatic
agents that, in contrast to most of the currently used
chemotherapeutic drugs, do not target DNA or the
cytoskeleton but act at the cell membrane [1]. There is
increasing interest in the biological activity of these lipid
analogs as they selectively inhibit the growth of trans-
formed cells and could well complement existing DNA-
directed anticancer chemotherapies. Miltefosine (hexa-
decylphosphocholine) belongs to the alkylphosphocho-
line (APC) group, which exert antitumor activity against
a broad spectrum of established tumor cell lines and
solid tumors [2-5]. The inhibition of tumor cell prolif-
eration caused by these agents may be the result not
only of direct cell damage but also because of the induc-
tion of apoptosis [6]. Initial clinical studies have shown
promising results; for example, miltefosine may be used
for the topical treatment of cutaneous metastases of
mammary carcinomas [7]. Remarkably, miltefosine exhi-
bits potent leishmanicidal activity as a consequence of
its interference with the parasite’s metabolic pathways
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reproduction in any medium, provided the original work is properly cited.[8]; thus, orally administered miltefosine has been
reported to be efficacious against the visceral and cuta-
neous forms of leishmaniasis [9,10]. Miltefosine is also
toxic in vitro to other protozoan parasites [11-13].
Miltefosine is a representative member of a second
generation of the synthetic APL family, being the proto-
type of the first generation edelfosine. In an attempt to
improve antitumor activity with reduced side effects,
erucylphosphocholine and perifosine appeared (Figure 1).
Compared to miltefosine, erucylphosphocholine contains
a longer hydrocarbon chain with a cis double bond and
perifosine presents a piperi d i n em o i e t yi n s t e a do ft h e
choline head group [1]. A wide variety of molecular
mechanisms have been proposed to explain the antitu-
mor activity of distinct membrane-directed APLs [14],
whose action appears to depend on the cell type [15],
t h eu p t a k er a t ei n t ot h ec e l l[ 1 6 ]a n dt h ec o m p o u n d
under study. Due to their chemical structure, APLs
easily insert into lipid membranes and resist catabolic
degradation; the level of partitioning into lipid bilayers
depends on the degree of unsaturation of phospholipid
alkyl chains and the amount of cholesterol. Miltefosine
interacts with the cell membrane and rapidly reaches
other subcellular membranes [17,18], being able to affect
cell metabolism at different levels. The enzymes
involved in lipid metabolism are mainly located in the
membranes of the endoplasmic reticulum (ER) and thus
would be a target for miltefosine activity. Until now its
mode of action has not been precisely established,
although the membrane appears to be the primary site
of its activity, most likely due to interference with lipid
metabolism and lipid-dependent signal transduction
[1,8]. Effects induced by miltefosine upon a wide range
of cellular processes such as the modulation of calcium
homeostasis [19], alterations of phospholipase C [20],
phospholipase A2 [21] or phospholipase D activity [22],
Figure 1 Chemical structure of synthetic alkylphospholipids used in our studies. The structures were adapted from [70].
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dylcholine (PtdCho) metabolism (reviewed in [25]) has
led to several hypotheses being put forward to explain
how it works, one of these being that it may arrest
tumor cell proliferation by interfering with the biosynth-
esis of PtdCho.
This review will mainly focus on the actions of milte-
fosine in the human hepatoma HepG2 cell line, a well-
established model to examine hepatic lipid transport
and metabolism, with emphasis on the alterations
caused by miltefosine in the homeostasis of phospholi-
pids and cholesterol. Additionally, the effects of other
APLs with potential clinical relevance, such as edelfo-
sine, erucylphosphocholine and perifosine will be also
described.
Effects of miltefosine on glycerolipid and sphingolipid
metabolism
Influence of miltefosine upon glycerolipid metabolism
Preliminary studies in our laboratory demonstrated that
nontoxic concentrations of miltefosine exert an antipro-
liferative effect on cultured HepG2 cells; e.g., a concen-
tration of 50 μM miltefosine for 48 h caused a decrease
in the number of cells, without a significant loss of via-
bility, in the presence of serum. These findings agree
with those encountered in MDCK [26], HeLa [27] and
other neoplastic cell lines [2], indicating that HepG2
cells are moderately sensitive to the toxic effects (doses
higher than 100 μM) and cytostatic activity of miltefo-
sine concentrations in the micromolar range.
Our research group [28] and others [2,3,29] have
shown that miltefosine inhibits the synthesis of PtdCho
via CDP-choline (Figure 2). As far as the soluble inter-
mediates in the CDP-choline pathway are concerned, we
have found that treatment of HepG2 cells with miltefo-
sine produces a significant increase in the label of cho-
line phosphate and a decrease in that of CDP-choline
compared to the untreated cells. Thus, the inhibitory
effect produced by miltefosine on PtdCho synthesis in
these cells seems to be the consequence of an alteration
in CTP:phosphocholine cytidylyltransferase (CT) activity.
In fact, the exposure of HepG2 cells to miltefosine
caused a dose-dependent increase in cytosolic CT activ-
ity and this was accompanied by a concomitant decrease
in membrane-bound CT activity in the cell particulate
fraction, while the total CT activity was unaltered.
Therefore, this APC interferes with PtdCho biosynthesis
by impairing the translocation of the rate-limiting
enzyme CT from the cytosol, where it is inactive, to
membranes, where it expresses activity; that is, it affects
only the distribution of CT. Miltefosine did not inhibit
particulate CT activity in vitro, i.e., at the membrane
level, but did inhibit cytosolic CT activity in the pre-
sence of low amounts of activating PtdCho/oleate
liposomes. Thence, miltefosine appears to hinder the
insertion of the soluble CT form into lipid vesicles or
the membrane to become activated. Interestingly, simul-
taneous exposure of cells to oleate increased CT activity
hereby stimulating PtdCho synthesis and it drastically
reversed the inhibitory effect of miltefosine on PtdCho
formation [28]. The reduction in PtdCho biosynthesis
was shown not to be due to any alteration in choline
uptake by the HepG2 cells, a finding which agrees with
that found in MDCK cells [29], but it does go against
observations made in neuronal cells [30] and KB and
Raji cells [31]. In the latter cells, an increase in the
degradation of PtdCho was also apparent after miltefo-
sine treatment [31]. The inhibition of PtdCho synthesis
in the HepG2 cell line after miltefosine incubation was
not related to any alterationi nt h ed e g r a d a t i o nr a t eo f
PtdCho or its secretion into the culture medium; in
addition, treatment with miltefosine altered neither the
activity of cytosolic choline kinase nor that of mem-
brane-bound diacylglycerol cholinephosphotransferase
[28].
It is noticeable that induction of apoptosis by distinct
APLs in lymphoma cells occurs through inhibition of
CTP:phosphocholine CT after internalization via raft-
mediated endocytosis [32,33]. Since PtdCho is involved
in cell-signaling processes, minor alterations in its levels
may contribute negatively to cell survival. In fact, slight
changes in PtdCho levels occurred in MDCK cells after
24 h of miltefosine treatment [34]. Having in mind that
specific alterations in lipid metabolism could be involved
in programmed cell-death processes, we have provided
experimental evidence for the induction of apoptosis by
miltefosine in HepG2 cells. After prolonged treatment
with miltefosine, the tumoral cells showed a clearly
rounded morphology and became increasingly detached
from the plate. In addition, cells exposed to miltefosine
for more than 24 h showed typical features of apoptosis,
such as DNA laddering and caspase-3 activation. Thus,
apoptotic cell death induced by miltefosine in the
HepG2 cells appears to involve, at least, an increased
caspase-3-like protease activity and genomic DNA frag-
mentation [28].
Incubation of HepG2 cells with miltefosine was also
shown to increase the de novo biosynthesis of triacylgly-
cerol (TAG) and PtdEtn [35]. The combined enhance-
ment of TAG and PtdEtn syntheses may be attributed
in part to the higher availability of diacylglycerol for gly-
cerolipid biosynthesis when the synthesis of PtdCho is
inhibited, as illustrates in Figure 2. On the other hand,
the release of PtdCho into the medium remained unal-
tered while that of TAG increased somewhat in the pre-
sence of miltefosine, indicating that the apparent effects
of miltefosine on cellular glycerolipid synthesis in the
HepG2 cells were not due to an alteration of lipid
Jiménez-López et al. Lipids in Health and Disease 2010, 9:33
http://www.lipidworld.com/content/9/1/33
Page 3 of 10secretion into the medium; in addition, miltefosine did
not significantly affect metabolic turnover of prelabeled
glycerolipids, e.g., PtdCho, as indicated above.
Concerning the synthesis of PtdEtn, we analyzed the
water-soluble intermediates and final product, PtdEtn, of
the CDP-ethanolamine pathway and found that miltefo-
sine causes a modest increase in the incorporation of
radiolabeled ethanolamine into CDP-ethanolamine and
PtdEtn and a decrease in ethanolamine phosphate,
which might be interpreted in terms of a stimulation of
CTP:phosphoethanolamine CT activity, the rate-limiting
enzyme of this metabolic pathway. Even though these
changes might be attributed to miltefosine stimulating
the synthesis of PtdEtn in HepG2 cells, the effect was
quite slight, the radioactivity in PtdEtn increasing by
only 10% compared to controls [36]. It has been
reported that miltefosine treatment enhances the
amount of PtdEtn in the membranes of Leishmania
donovani promastigotes [10]. Moreover, the ether lipid
edelfosine increases the production of CDP-ethanola-
mine and hence enhances PtdEtn synthesis in MCF-7
cells [37]. Since PtdEtn can be methylated in the ER to
give PtdCho, we analyzed this process and observed that
miltefosine significantly decreases the microsomal synth-
esis of PtdCho from PtdEtn by inhibiting PtdEtn N-
methyltransferase activity [36]. These results constituted
the first experimental evidence that the inhibition of the
synthesis of PtdCho via CDP-choline by miltefosine is
not counterbalanced by any increase in its formation via
methylation. On the contrary, in the presence of milte-
fosine both pathways seem to contribute jointly to a
decrease in the overall synthesis of PtdCho in HepG2
cells, as shown in Figure 2.
The uptake of radioactive serine into phosphatidylser-
ine (PtdSer) and other phospholipids remained
unchanged by miltefosine and neither was the activity of
either PtdSer synthase or mitochondrial PtdSer decar-
boxylase (to give PtdEtn) altered, demonstrating that the
biosynthesis of PtdSer is unaffected by miltefosine in
HepG2 cells [36]. Treatment of the human lymphoma
Raji cell line with miltefosine also led to an inhibition of
PtdCho synthesis via CDP-choline, but enhanced, how-
ever, the generation of PtdCho from PtdSer via decar-
boxylation and methylation processes as a compensatory
mechanism [38], suggesting that the effect of miltefosine
on cellular phospholipid metabolism may well differ
depending upon the cell type.
Influence of miltefosine upon sphingolipid metabolism
With regard to sphingolipid metabolism, we found that
exposure of HepG2 cells to miltefosine produces a
marked time-dependent inhibition of sphingomyelin
(SM) synthesis, using radiolabeled palmitate as exogen-
ous substrate [39]. An accumulation of ceramide was
Figure 2 Diagram for the hepatic biosynthetic pathways of phospholipids and triacylglycerol. Several radiolabeled lipid precursors are
depicted as outlined within the text. The postulated mode of action of miltefosine on specific metabolic steps is included. It is noteworthy that
miltefosine inhibits the synthesis of both choline-bearing phospholipids, PtdCho and SM.
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could well be a result of diminished SM synthesis [35].
Thus, early treatment with the APC brings about a clear
decrease in the SM/ceramide ratio. These results agree
with findings reported in HaCaT cells, showing that the
incorporation of choline into SM is inhibited by miltefo-
sine concomitantly with an increase in intracellular
ceramide levels [3]. Due to the precursor-product rela-
tionship, the biosynthesis of SM catalyzed by SM
synthase might be influenced by the inhibition of the
PtdCho synthetic pathway in the presence of miltefo-
sine. On the other hand, incubation of HepG2 cells with
miltefosine did not seem to alter the degradation of SM
via sphingomyelinase activity, in accordance with pre-
vious observations in human leukemia cells [40].
Keeping a strict balance in the composition and rela-
tive proportions of phospholipids is of vital importance
to the integrity of the cell membrane. Hence, it is worth
emphasizing that early miltefosine treatment may affect
lipid homeostasis and hereby cell membrane function by
decreasing the synthesis of choline-bearing phospholi-
pids, that is, PtdCho and SM (Figure 2), which are key
membrane lipid components. Thus, subtle changes in
these phospholipid pools may exert significant effects on
the biological response of cells to miltefosine treatment.
Disruption of cellular cholesterol transport and
metabolism by alkylphospholipids
Overall picture of intracellular cholesterol trafficking
and metabolism
Cholesterol is an essential constituent in the membrane
of the mammalian cells, therefore abnormalities affecting
cholesterol homeostasis result in several pathological
conditions, notably atherosclerosis, Alzheimer’s and Nie-
mann-Pick type C (NPC) diseases. The cells obtain cho-
lesterol by taking it up from their environment, mostly
in the form of low-density lipoproteins or by de novo
synthesis [41]. Cholesterol homeostasis in the hepatic
cell is regulated by a complex set of mechanisms that
include cholesterol biosynthesis, hydrolysis of cholesteryl
esters (CE) from lipoproteins internalized into lyso-
somes, and transport of released cholesterol to intracel-
lular organelles, such as the ER, for its esterification and
conversion into bile acids [42]. Many aspects of the
hepatic metabolism of cholesterol are well known,
including its synthesis in the ER, its extracellular trans-
port in plasma lipoproteins, its uptake by the low-den-
sity lipoprotein receptor (LDLR), and its regulation via
sterol regulatory element-binding proteins (SREBPs).
The pathways involved in cholesterol metabolism are
strictly related to its transport and intracellular distribu-
tion among subcellular organelles and the plasma mem-
brane (PM) [41]. Nevertheless, these pathways and their
molecular regulation are still only partially understood.
The difficulty comes from the interconnection between
the different pools of intracellular cholesterol and the
variety of mechanisms that can operate simultaneously
to transport cholesterol within cells, including vesicular
and nonvesicular transport [43].
Three organelles are involved in cholesterol trafficking
(Figure 3): (1) ER, the major site of synthesis, regulation
and esterification of choles t e r o l ,( 2 )P M ,ap r o m i n e n t
storage site for unesterified cholesterol, and (3) endo-
somes/lysosomes, where lipoprotein-derived cholesterol
is liberated. Endocytosed LDL are delivered rapidly to
lysosomes; the protein/phospholipid coat is degraded
and CE are hydrolyzed to cholesterol [44]. Most, per-
haps all, of this cholesterol is transported directly to the
PM [45], which contains approximately 65-80% of the
unesterified cholesterol in the cell [46]. Cholesterol
synthesized in the ER, as well as that released in the
endosomes/lysosomes by lipoprotein catabolism, moves
to the PM against a steep concentration gradient
[41,47]. Once the capacity of the PM and other com-
partments to absorb cholesterol is exceeded, cholesterol
is transported back to the ER, where it is esterified by
acyl-CoA:cholesterol acyltransferase (ACAT), regulates
3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR)
proteolysis, and inhibits proteolytic processing of
SREBP2, which is required for expression of sterol-regu-
lated genes [48]. This distribution of cholesterol between
sites of regulation, synthesis, and deposition provides an
efficient control for cellular cholesterol levels. With the
exception of the SCAP (SREBP cleavage-activating
protein) system, the complex control mechanisms for
regulating cholesterol levels in different cellular com-
partments remain largely unknown.
Maintenance of the cycle between free and esterified
cholesterol relies on the bidirectional transport of sterols
between the ER and the PM and/or an endocytic com-
partment. Proper control of this transport is important
for normal cell function and development, as indicated
by fatal human pathologies such as NPC disease and
atherosclerosis, which are characterized by an over-
accumulation of free sterols within the endosomal mem-
branes and the ER, respectively [49]. Two independent
NPC genes responsible for this neurodegenerative disor-
der have been identified, but the precise functions of the
encoded NPC1 and NPC2 proteins remain unknown
[50]. It is clear now that cholesterol travels from the PM
t ot h eE Rv i aad i f f e r e n tr o u t ef r o mt h a tt a k e nb yt h e
nascent cholesterol leaving it [41,51]. Plasma-membrane
cholesterol is thought to follow at least two pathways to
the ER: (1) a vesicular route via endosomes and (2) a
nonvesicular alternative route. Some amphiphilic drugs,
such as U18666A, progesterone and imipramine,
have been described as interfering with intracellular
sterol traffic by accumulating lysosomal unesterified
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cells [52,53]; the movement of cholesterol from the cell
surface to the ER is inhibited by these drugs, which also
affect cholesterol transport from the endosomes [54].
This defect in cholesterol transport causes cell damage
and mimics the cellular lesions observed in fibroblasts
from patients affected by NPC disease, characterized by
the accumulation of unesterified cholesterol and other
lipids in the endosomal/lysosomal compartment [55-57].
Effects of alkylphospholipids on cellular cholesterol
transport and metabolism
Our group has extensively examined the effects of the
antitumoral drug miltefosine on intracellular cholesterol
transport and metabolism and its relevance in maintain-
ing cholesterol homeostasis. It was shown that treatment
of HepG2 and Vero cells with miltefosine (also erucyl-
phosphocholine) significantly alters cholesterol metabo-
lism and leads to an accumulation of cholesterol in the
cell [35]. In fact, free cholesterol levels increased up to
3-fold when HepG2 cells were exposed to miltefosine
for 48 h. Using radiolabeled substrates we determined
the effect of this APC on cholesterol synthesis, the
destiny of cholesterol from LDL and the transport of
cholesterol between the PM and the ER. Long-term
exposure of HepG2 cells to miltefosine caused a marked
increase in cholesterol biosynthesis when acetate, but
not mevalonate, was used as the lipogenic precursor,
thereupon emerging HMGCR as a prime target for mil-
tefosine (Figure 4). This enzyme is an integral protein of
ER membranes, which is rate-limiting for cholesterol
synthesis and catalizes the production of mevalonate
from HMG-CoA. HMGCR is mainly regulated at the
transcriptional level through a negative-feedback
mechanism by the ER cholesterol pool [48]. Remarkably,
treatment with miltefosine induced higher activities of
HMGCR and the cell-surface LDLR in HepG2 cells, in
both a concentration- and time-dependent manner.
Furthermore, the steady-state protein levels and mRNA
expression of HMGCR and LDLR increased after incu-
bation with the APC. HMGCR activity was not, how-
ever, directly modulated by miltefosine as assayed in
vitro both in HepG2 cell lysates and rat-liver micro-
somes, and exposure of cells to miltefosine did not sig-
nificantly affect the decay rate of the reductase [58]. On
Figure 3 A model for intracellular cholesterol trafficking in mammalian cells. This figure was adapted from [42].
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nificantly change the expression of ACAT. These data
indicate that miltefosine stimulates the cholesterogenic
pathway as well as the receptor-mediated uptake of cho-
lesterol in HepG2 cells via an increase in the expression
of HMGCR and LDLR, respectively.
Uptake of cholesteryl linoleate in LDL and further
hydrolysis of these esters increased following exposure
of HepG2 cells to miltefosine. However, cholesterol
esterification from several radioactive exogenous fatty
acids was markedly reduced after treatment with milte-
fosine, even in the presence of the cholesterol analog
25-hydroxycholesterol added to the culture medium; in
addition, the reesterification rate of cholesterol from
LDL decreased after treatment with the APC [35,58].
This inhibition of intracellular CE synthesis was obser-
vable after only one hour of exposure to miltefosine
[39]. In general, the concentration of CE is a result of
the balance between cholesterol esterification and
hydrolysis of CE. The latter mainly results from the
activity of neutral CE hydrolase (nCEH), which resides
in cytosolic lipid droplets, while the ER-localized
enzyme ACAT is responsible for the esterification of
excess cholesterol, and hence plays a key role in cellular
cholesterol homeostasis (Figure 3). We investigated the
action of miltefosine on the synthesis and hydrolysis of
CE in cell homogenates and found that ACAT activity
appears to decrease in response to miltefosine, since a
reduction of fatty-acid incorporation into CE was
observed [35]. Afterwards, we confirmed that the appar-
ent inhibition of ACAT after treatment with miltefosine
was due to a depletion of ER-associated cholesterol pool
[58]. On the other hand, nCEH activity was not affected
when the cells were exposed to miltefosine [35].
All these observations point to the fact that miltefo-
sine in general alters cholesterol metabolism. The
observed increase in cholesterol synthesis brought about
by miltefosine treatment and the decrease in cholesterol
esterification disturb the intracellular cholesterol/CE
cycle and lead to high levels of unesterified cholesterol in
HepG2 cells. An increased content of cholesterol in
membranes from miltefosine-treated Leishmania dono-
vani promastigotes has also been reported [10], neverthe-
less it involves exogenous cholesterol recruitment within
the parasite membranes and appears to depend on a
direct interaction between miltefosine and sterols [59].
It has been suggested that CE might serve as a
dynamic reservoir, its synthesis being controlled by
ACAT activity, which would be regulated by the supply
of cholesterol in the ER [42]. Bearing in mind that cho-
lesterol esterification is a measure of the levels of free
cholesterol arriving at the ER, our data suggested that
miltefosine treatment could interfere with CE synthesis
owing to a reduction in the amount of plasma-mem-
brane cholesterol fluxing to the ER and hereby lower
cholesterol levels in the ER regulatory pool. Thus, we
used the degree of esterification of plasma-membrane
cholesterol as a marker of retrograde cholesterol move-
ment from the cell surface to the ER, the site of ACAT
activity [42,60]. Treatment with miltefosine was found
to produce a marked decrease in the esterification of
plasma-membrane cholesterol, indicating that the move-
ment of cholesterol from the PM to the ER is disrupted
by miltefosine [58]. Particularly, we showed that esterifi-
cation of plasma-membrane cholesterol in cells exposed
to miltefosine for a short 1-h period of time was also
acutely reduced, and this effect was similar both in con-
trol and energy-depleted cells, hereby demonstrating
that the APC alters mainly the nonvesicular intracellular
cholesterol transport [39].
In addition to synthesizing cholesterol, mammalian
cells also synthesize substantial amounts of precursor
Figure 4 Basic scheme for cholesterol biosynthesis from radiolabeled acetate or mevalonate as precursors. The postulated mode of
action of miltefosine on specific metabolic steps is included. Enzyme abbreviations: HMGCS1 (cytosolic HMG-CoA synthase); HMGCR (HMG-CoA
reductase); FDPS (farnesyl diphosphate synthase); FDFT1 (farnesyl-diphosphate farnesyltransferase 1, also known as squalene synthase); LDLR
(low-density lipoprotein receptor).
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the ER and rapidly reach the PM [61,62] and then move
back to the ER to be enzymatically processed to choles-
terol, being this movement essential to complete choles-
terol biosynthesis. It has been shown that when traffic
of cholesterol from the PM to the ER is disrupted, the
circuit for synthesis of this sterol is affected, so inter-
mediates of cholesterol biosynthesis are accumulated
[62,63]. In fact, we found that the contribution of des-
mosterol and 7-dehydrocholesterol to the total C27
sterol synthesis increased 4-fold in HepG2 cells after 24
h of treatment with miltefosine, hereby increasing the
ratio of sterol biosynthetic intermediates to cholesterol,
the final product of this pathway [39]. Therefore, our
results suggest that this APC not only interferes with
the intracellular cholesterol traffic but also with the
transport of these intermediates back to the ER for com-
pletion of cholesterol synthesis.
Hydrolysis of SM in the PM by treatment of HepG2
cells with exogenously added bacterial sphingomyelinase
resulted in an enhanced fluxing and esterification of
PM-associated cholesterol into the ER, as previously
reported in other cell lines [64]; however, simultaneous
exposure to sphingomyelinase did not prevent the inhi-
bition of retrograde PM-to-ER cholesterol traffic and CE
formation brought about by miltefosine treatment [39].
Moreover, the increase induced by miltefosine in the
cholesterogenic activity and the inhibition of cholesterol
esterification also occurred in the presence of exogen-
ously added LDL-cholesterol [58]. On the contrary,
exposure to this drug had no effect on the arrival of
endosomal/lysosomal cholesterol to the PM, released
from LDL internalized via the clathrin-mediated endocy-
tic pathway, or the movement of endogenously synthe-
sized cholesterol from the ER to the cell surface, where
it can be extracted using cyclodextrin as aceptor. In
order to confirm that the results were not a unique or
unusual effect specific to HepG2 cells, we also made
experiments with Vero cells and found a similar profile
of changes induced by miltefosine upon the synthesis of
cholesterol and CE [39]. Thus, the main mechanism by
which miltefosine impairs cholesterol homeostasis and
causes the accumulation of cholesterol within the cell is
altering the nonvesicular, energy-independent transport
of cholesterol from the PM to the ER (Figure 3).
Our most recent observations indicate that exposure
to nonlytic concentrations of other membrane-active
APLs such as edelfosine, erucylphosphocholine and peri-
fosine decrease the proliferation rate of cultured HepG2
cells. Likewise, these agents alter intracellular cholesterol
transport and metabolism in a manner similar to milte-
fosine, that is, they impaire cholesterol trafficking from
the PM to intracellular membranes and, as a result, pro-
duce a remarkable decrease in cholesterol esterification,
hence leading to an enhancement of cholesterol synth-
esis and LDL-cholesterol uptake in the hepatoma
HepG2 cell line [65].
Cholesterogenesis is known to be transiently induced
by the translocation of the transcription factor SREBP2
from the ER membrane (125-kDa precursor form) to
the nucleus (70-kDa mature form) [66]. In fact, incuba-
tion of cells with miltefosine or edelfosine stimulated
gene expression of SREBP2 as well as transcription of
the SREBP2-responsive LDLR gene. In addition, expo-
sure to miltefosine or edelfosine increased the mRNA
transcript levels of cholesterol-synthesizing enzymes
such as cytosolic HMG-CoA synthase (HMGCS1),
HMGCR, farnesyl diphosphate synthase (FDPS) and far-
nesyl diphosphate farnesyltransferase-1 (FDFT1, also
known as squalene synthase) (Figure 4), which are tran-
scriptionally-regulated, rate-limiting enzymes of the cho-
lesterol biosynthetic pathway [67]. Moreover, incubation
of HepG2 cells with the different APLs produced a
time-dependent increase of mature SREBP2 form in the
assayed cell lysates as well as increased protein levels of
its targets HMGCR and LDLR. As a likely consequence,
cell exposure to miltefosine enhanced the content of
cholesterol mainly in the membrane raft fractions (iso-
lated by a detergent-free disruption procedure) and
hence the cholesterol/SM ratio was clearly increased by
miltefosine treatment, as compared to the untreated
cells [65].
Cholesterol and SM are major lipid constituents of
membrane raft microdomains, and the ratio cholesterol/
SM is crucial to maintain the integrity of lipid rafts and
thence membrane functionality. Consequently, the dis-
turbance of this ratio could alter several signaling path-
ways associated to these membrane domains [68,69] and
be involved in the biological actions exhibited by milte-
fosine and other APLs in different cell types.
Conclusions
The bulk of our data indicates that miltefosine impairs
cholesterol arrival into the ER, without altering reverse
cholesterol trafficking from the ER to the PM, leading
to a depletion of free cholesterol in the ER and conse-
quently a deregulation of cholesterol biosynthesis and
receptor-mediated cholesterol uptake. The final result of
this interference is an increased uptake, synthesis and
accumulation of cholesterol within the cell. Together
with the reduction in PtdCho and SM syntheses induced
by miltefosine, all these effects lead to an alteration in
the choline-containing phospholipid/cholesterol ratio
that can disturb membrane stability and function, and
thus might be expected to inhibit tumor cell growth.
Therefore, the imbalance in this ratio may well be partly
responsible for the induction of apoptosis and the anti-
proliferative activity exhibited by this APC in HepG2
Jiménez-López et al. Lipids in Health and Disease 2010, 9:33
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Page 8 of 10cells. We have recently found that other membrane-
directed APLs such as edelfosine, erucylphosphocholine
and perifosine also alter intracellular cholesterol home-
ostasis. Cholesterogenic response induced by APLs in
HepG2 cells involves an increased gene expression and
higher levels of several proteins related to the pathway
of biosynthesis as well as the receptor-mediated uptake
of cholesterol. All these alterations may affect mem-
brane lipid composition and their distribution in raft-
nonraft domains.
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